Corrigendum: Cipaglucosidase alfa plus miglustat: linking mechanism of action to clinical outcomes in late-onset Pompe disease

Documenti analoghi

• Corrigendum: Cipaglucosidase alfa plus miglustat: linking mechanism of action to clinical outcomes in late-onset Pompe disease
  di: Barry J. Byrne, et al.
  Pubblicazione: (2025-01-01)
• Improved Enzyme Replacement Therapy with Cipaglucosidase Alfa/Miglustat in Infantile Pompe Disease
  di: Lina Fiege, et al.
  Pubblicazione: (2023-08-01)
• Miglustat: a first-in-class enzyme stabilizer for cipaglucosidase alfa for the treatment of late-onset Pompe disease
  di: Robert J. Hopkin, et al.
  Pubblicazione: (2026-02-01)
• Switching treatment to cipaglucosidase alfa plus miglustat positively affects patient-reported outcome measures in patients with late-onset Pompe disease
  di: Priya S. Kishnani, et al.
  Pubblicazione: (2024-11-01)
• Comparing the efficacy of cipaglucosidase alfa plus miglustat with other enzyme replacement therapies for late-onset Pompe disease: a network meta-analysis utilizing patient-level and aggregate data
  di: Simon Shohet, et al.
  Pubblicazione: (2024-09-01)